RAPT Therapeutics, Inc. RAPT 深 沪
已收盘 03-03 16:00:00 美东时间
58.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 58.00
- 总市值 171.94万
- 52周最高 58.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.7082
- 委 比 0.00%
- 总股本 2.96万
- 历史最高 58.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.7082
- 每 手 1
- 风险率 18.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play
GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary hypertension affecting millions worldwide.
02-25 20:22
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
RAPT Therapeutics appoints Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors, adding expertise to advance RPT904, a monoclonal antibody for allergic diseases, through Phase 2 trials in CSU, asthma, and food allergy.
2025-06-23 12:00
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
RAPT Therapeutics将实施1:8反向股票拆分，于6月16日生效，17日起以新CUSIP号交易。此举将流通股数由约1.323亿降至1650万，影响股票期权、warrants及激励计划。
2025-06-13 13:00
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics announced that its management team will participate in two investor conferences in June: the Goldman Sachs Global Healthcare Conference on June 10 and the UBS Biotech Conference on June 24.
2025-06-04 20:05
冷门大赛道爆了
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 荨麻疹这个疾病领域爆了。 短短几天内该领域传出了诺华Remibrutinib国内...
2025-03-09 19:02
UBS Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $2
UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $10 to $2.
2024-09-09 22:23
HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.
2024-08-20 19:16
